This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The sequencing data obtained in this study were deposited in the Sequence Read Archive (SRA) of NCBI (SRA; accession codes PRJNA672227, PRJNA690872, and PRJNA672228).
References
Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.
Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–3.
Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019;25:1839–42.
Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Disco. 2016;6:154–65.
Durham BH. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol. 2019;86:62–76.
Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, et al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017;130:1007–13.
Cohen Aubart F, Roos-Weil D, Armand M, Marceau-Renaut A, Emile JF, Duployez N, et al. High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood. 2020;137:485–92.
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:60–87.
Cao XX, Niu N, Sun J, Cai H, Wang FD, Wang YN, et al. Clinical and positron emission tomography responses to long-term high-dose interferon-alpha treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis. 2019;14:11.
Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30:1367–77.
Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54:361–8.
Jouenne F, Chevret S, Bugnet E, Clappier E, Lorillon G, Meignin V, et al. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. Eur Respir J. 2020;55:1901190.
Chakraborty R, Burke TM, Hampton OA, Zinn DJ, Lim KP, Abhyankar H, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood. 2016;128:2533–7.
Foster SA, Whalen DM, Ozen A, Wongchenko MJ, Yin J, Yen I, et al. Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell. 2016;29:477–93.
Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E mutation: a significant biomarker for prediction of disease relapse in pediatric langerhans cell histiocytosis. Pediatr Dev Pathol. 2019;22:449–55.
Acknowledgements
The authors thank the patients and their families. This work was supported by institutional research funding provided by the Beijing Natural Science Foundation (Grant No. 7202160 to Cao XX), the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (Grant No. 2019-RC-HL-001 to Cao XX).
Author information
Authors and Affiliations
Contributions
XXC, JL, DBZ and MHD contributed to study conception and design; ALZ, HC and JC contributed to genomic analysis; ALZ, XMG and TL contributed to patient follow-up; LZ and HCC contributed to data analysis and interpretation; XXC, JL and MHD retrospectively reviewed patient records and contributed to data collection; JC, ALZ and XXC wrote the paper; JS and ZYL reviewed histological findings independently; and all authors revised the paper and approved the submitted version.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Chen, J., Zhao, Al., Duan, Mh. et al. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. Leukemia 36, 573–576 (2022). https://doi.org/10.1038/s41375-021-01439-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01439-3
This article is cited by
-
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis
Leukemia (2024)
-
Molecular Mutations in Histiocytosis: A Comprehensive Survey of Genetic Alterations
Molecular Biotechnology (2024)
-
Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis
Orphanet Journal of Rare Diseases (2023)
-
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease
Leukemia (2023)
-
Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement
Blood Cancer Journal (2023)